Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)
Conclusion The PANORAMA-HF study, which will be the largest prospective pediatric HF trial conducted to date and the first to use a global rank primary endpoint, will determine whether sacubitril/valsartan is superior to enalapril for treatment of pediatric HF patients with reduced systemic left ventricular systolic function. Graphical abstract
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Diovan | Enalapril | Heart | Heart Failure | Heart Transplant | Pediatrics | Study | Transplant Surgery | Transplants